Skip to content

Why become an eye donor?

Crosslinking is having a big impact on reducing the number of corneal transplants required for keratoconus. But not all patients can benefit and a small number of people still require a corneal transplant to restore their vision. As part of National DonateLife week, the head of the Victorian Lions Eye Donation Service, Dr Graeme Pollack,

Read More

Study: Epi-off CXL more effective for halting pediatric kc

An Italian study, recently published in Cornea, compared the effectiveness of epi-on versus epi off crosslinking in pediatric patients. The authors found that standard epi-off CXL halted keratoconus progression in 75% of eyes during the 3 years after treatment. By contrast, I-ON CXL seemed to slow down keratoconus progression in 50% of eyes, mainly in

Read More

Using the DUCK score to decide whether to crosslink

Question  Can adhering to the Dutch Crosslinking for Keratoconus (DUCK) score improve clinical decision making in patients with progressive keratoconus? Findings  This cohort study of 504 eyes and 388 patients found that adhering to the DUCK score was associated with a reduction in the overall crosslinking treatment rate without increasing the risk of disease progression.

Read More

Keratoconus: A family affair

Clinicians should screen close relatives of their patients with the condition. New data adds more weight to the theory that keratoconus is driven, in part, by genetics. Read more

Keratoconus: a French view

Listen to two French keratoconus experts discuss the latest treatments for this corneal disease and the evidence to support their use in this podcast from the The European Society of Cataract & Refractive Surgeons (ESCRS).

Why you are paying so much for surgery

ABC Four Corners produced this program Mind the Gap on why you are paying such high out-of-pocket expenses for surgery. A great guide to dealing with surgeons before surgery. Watch the program

Medicare rebate for corneal cross-linking

Thousands of Australians with keratoconus will benefit from a Medicare rebate of $1,200 for corneal collagen cross-linking as first line treatment to stop disease progression. read more